Xilio Therapeutics, Inc. (XLO) 10-Year Financial Performance & Capital Metrics

XLO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutXilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.Show more

Revenue $6M
EBITDA -$59M +23.7%
Net Income -$58M +23.8%
EPS (Diluted) -1.09 +60.8%
Gross Margin 100%
EBITDA Margin -929.04%
Operating Margin -954.95%
Net Margin -918.05%
ROE -214.02% -99.5%
ROIC -
Debt/Equity 0.46 +48.7%
Interest Coverage -605.82

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 94.6% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM588.4%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM62.21%

ROCE

10Y Avg-90.12%

5Y Avg-101.53%

3Y Avg-96.04%

Latest-136.47%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	6.34M
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	240K	1.06M	1.5M	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-240K	-1.06M	-1.5M	0	0	6.34M
Gross Margin %	-	-	-	-	-	1%
Gross Profit Growth %	-	-3.44%	-0.41%	1%	-	-
Operating Expenses+	18.79M	53.5M	73.55M	89.15M	79.13M	66.93M
OpEx % of Revenue	-	-	-	-	-	10.55%
Selling, General & Admin	4.53M	9.59M	22.36M	29.95M	27M	24.78M
SG&A % of Revenue	-	-	-	-	-	3.91%
Research & Development	14.26M	43.91M	51.19M	59.2M	52.14M	41.21M
R&D % of Revenue	-	-	-	-	-	6.5%
Other Operating Expenses	0	0	0	0	0	937K
Operating Income+	-19.03M	-54.56M	-75.04M	-89.15M	-79.13M	-60.58M
Operating Margin %	-	-	-	-	-	-9.55%
Operating Income Growth %	-	-1.87%	-0.38%	-0.19%	0.11%	0.23%
EBITDA+	-18.79M	-53.5M	-73.55M	-87.3M	-77.23M	-58.94M
EBITDA Margin %	-	-	-	-	-	-9.29%
EBITDA Growth %	-	-1.85%	-0.37%	-0.19%	0.12%	0.24%
D&A (Non-Cash Add-back)	240K	1.06M	1.5M	1.85M	1.9M	1.64M
EBIT	-17.31M	-54.62M	-75.2M	-89.15M	-79.13M	-59.65M
Net Interest Income+	0	-599.4K	-599.4K	0	0	-100K
Interest Income	0	600	600	0	0	0
Interest Expense	0	600K	600K	0	0	100K
Other Income/Expense	1.72M	-656K	-756K	927K	2.73M	2.34M
Pretax Income+	-17.31M	-55.22M	-75.8M	-88.22M	-76.4M	-58.24M
Pretax Margin %	-	-	-	-	-	-9.18%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-17.31M	-55.22M	-75.8M	-88.22M	-76.4M	-58.24M
Net Margin %	-	-	-	-	-	-9.18%
Net Income Growth %	-	-2.19%	-0.37%	-0.16%	0.13%	0.24%
Net Income (Continuing)	-17.31M	-55.22M	-75.8M	-88.22M	-76.4M	-58.24M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.06	-2.01	-2.72	-3.19	-2.78	-1.09
EPS Growth %	-	-30.9%	-0.35%	-0.17%	0.13%	0.61%
EPS (Basic)	-0.06	-2.01	-2.72	-3.19	-2.78	-1.09
Diluted Shares Outstanding	274.69M	27.47M	27.36M	27.39M	27.5M	53.51M
Basic Shares Outstanding	274.69M	27.47M	27.36M	27.39M	27.5M	53.51M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	51.1M	20.59M	202.52M	124.5M	48.13M	60.23M
Cash & Short-Term Investments	48.84M	19.24M	198.05M	120.39M	44.7M	55.29M
Cash Only	48.84M	19.24M	198.05M	120.39M	44.7M	55.29M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	1.01M	0	4.46M	4.11M	3.42M	4.94M
Total Non-Current Assets+	11.62M	15.73M	19.08M	14.67M	12.8M	10.84M
Property, Plant & Equipment	9.87M	14.06M	13.9M	12.84M	11.2M	9.06M
Fixed Asset Turnover	-	-	-	-	-	0.70x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	194K	0	1.55M	1.56M	0	1.78M
Other Non-Current Assets	1.55M	1.66M	90K	267K	1.6M	0
Total Assets+	62.72M	36.32M	221.6M	139.16M	60.93M	71.08M
Asset Turnover	-	-	-	-	-	0.09x
Asset Growth %	-	-0.42%	5.1%	-0.37%	-0.56%	0.17%
Total Current Liabilities+	5.21M	22.16M	12.78M	21.12M	15.96M	27.26M
Accounts Payable	2.52M	5.44M	3.14M	3.13M	1.05M	2.57M
Days Payables Outstanding	3.83K	1.87K	765.55	-	-	-
Short-Term Debt	0	2.33M	883K	6.67M	3.31M	0
Deferred Revenue (Current)	0	0	0	0	0	1000K
Other Current Liabilities	1.92M	0	3.61M	82K	6.9M	4.21M
Current Ratio	9.81x	0.93x	15.85x	5.89x	3.02x	2.21x
Quick Ratio	9.81x	0.93x	15.85x	5.89x	3.02x	2.21x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	19M	19.45M	23.39M	12.4M	8.14M	26.22M
Long-Term Debt	9.61M	7.81M	9.63M	3.17M	0	0
Capital Lease Obligations	9.02M	11.1M	10.22M	9.19M	8.14M	6.95M
Deferred Tax Liabilities	0	0	3.54M	0	0	0
Other Non-Current Liabilities	374K	540K	0	45K	0	0
Total Liabilities	24.21M	41.6M	36.17M	33.52M	24.1M	53.48M
Total Debt+	18.63M	21.89M	20.74M	19.94M	11.46M	8.14M
Net Debt	-30.21M	2.65M	-177.32M	-100.45M	-33.25M	-47.15M
Debt / Equity	0.48x	-	0.11x	0.19x	0.31x	0.46x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-90.94x	-125.07x	-	-	-605.82x
Total Equity+	38.51M	-5.29M	185.43M	105.65M	36.83M	17.6M
Equity Growth %	-	-1.14%	36.09%	-0.43%	-0.65%	-0.52%
Book Value per Share	0.14	-0.19	6.78	3.86	1.34	0.33
Total Shareholders' Equity	38.51M	-5.29M	185.43M	105.65M	36.83M	17.6M
Common Stock	0	0	3K	3K	3K	5K
Retained Earnings	-29.87M	-85.09M	-160.89M	-249.11M	-325.51M	-383.75M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.84M	-36.09M	-80.75M	-75.72M	-68.62M	-18.38M
Operating CF Margin %	-	-	-	-	-	-2.9%
Operating CF Growth %	-	-1.02%	-1.24%	0.06%	0.09%	0.73%
Net Income	-17.31M	-55.22M	-75.8M	-88.22M	-76.4M	-58.24M
Depreciation & Amortization	240K	1.06M	1.5M	1.85M	1.9M	1.64M
Stock-Based Compensation	112K	1.3M	4.96M	0	0	6.43M
Deferred Taxes	-1.74M	0	222K	0	0	0
Other Non-Cash Items	56K	165K	173K	8.65M	7.54M	3K
Working Capital Changes	797K	16.6M	-11.8M	2M	-1.66M	31.78M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	970K	2.93M	-2.82M	485K	-2.06M	1.53M
Cash from Investing+	-715K	-2.19M	-1.1M	-1.87M	-486K	-36K
Capital Expenditures	-715K	-2.19M	-1.1M	-1.87M	-486K	-36K
CapEx % of Revenue	-	-	-	-	-	0.01%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	60.02M	10.03M	260.67M	-69K	-6.55M	29.2M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-9.95M	159K	-467K	0	0	25.75M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-18.56M	-38.28M	-81.85M	-77.59M	-69.11M	-18.41M
FCF Margin %	-	-	-	-	-	-2.9%
FCF Growth %	-	-1.06%	-1.14%	0.05%	0.11%	0.73%
FCF per Share	-0.07	-1.39	-2.99	-2.83	-2.51	-0.34
FCF Conversion (FCF/Net Income)	1.03x	0.65x	1.07x	0.86x	0.90x	0.32x
Interest Paid	14K	536K	492K	0	0	62K
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-44.95%	-332.39%	-84.15%	-60.62%	-107.25%	-214.02%
Return on Invested Capital (ROIC)	-	-1446.27%	-2056%	-1004.46%	-1351.78%	-
Gross Margin	-	-	-	-	-	100%
Net Margin	-	-	-	-	-	-918.05%
Debt / Equity	0.48x	-	0.11x	0.19x	0.31x	0.46x
Interest Coverage	-	-90.94x	-125.07x	-	-	-605.82x
FCF Conversion	1.03x	0.65x	1.07x	0.86x	0.90x	0.32x

Frequently Asked Questions

Growth & Financials

Xilio Therapeutics, Inc. (XLO) reported $31.8M in revenue for fiscal year 2024.

Xilio Therapeutics, Inc. (XLO) grew revenue by 0.0% over the past year. Growth has been modest.

Xilio Therapeutics, Inc. (XLO) reported a net loss of $58.5M for fiscal year 2024.

Dividend & Returns

Xilio Therapeutics, Inc. (XLO) has a return on equity (ROE) of -214.0%. Negative ROE indicates the company is unprofitable.

Xilio Therapeutics, Inc. (XLO) had negative free cash flow of $17.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener